ENOV — Enovis Corporation

Summary of Enovis Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Performance:

  • Revenue: $576 million, up 3% year-over-year (2% organic growth).
  • Adjusted EBITDA Margin: 17.9%, flat year-over-year.
  • Adjusted EPS: $3.30, a 16% increase.
  • Free Cash Flow: $20 million, returning to positive after a negative 43% in the prior year.

• Full Year 2025 Performance:

  • Total Revenue: $2.2 billion, representing 7% reported growth (6% organic growth).
  • Adjusted Gross Margin: 61%, up 170 basis points.
  • Interest Expense: $35 million, down from $57 million in the previous year.
  • Leverage Ratio: Reduced to 3.1x.

2. Strategic Updates and Business Highlights

• Key Priorities: Focus on commercial execution, operational excellence, and financial discipline.
• Portfolio Transformation: Significant progress in reshaping the portfolio, with a strong emphasis on innovation and cross-selling synergies.
• Product Launches: Successful launches of the Nebula Stent and OrthoDrive Impactor, with expectations for continued growth in extremities.
• Innovation Pipeline: 50% more 510(k) clearances than previous years, with a robust pipeline of new products planned for the next 24 months.
• One Enovis Initiative: Aiming for improved collaboration and efficiency across business units to enhance performance.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $2.31 billion and $2.37 billion, with mid-single-digit organic growth (4% to 6%).
• Adjusted EBITDA Guidance: Projected range of $425 million to $435 million, indicating a 50 basis point margin improvement.
• Free Cash Flow Conversion: Targeting over 25% in 2026, with a pathway to 70% to 80% in subsequent years.

4. Bad News, Challenges, or Points of Concern

• Goodwill Impairment: A noncash impairment of $501 million was recorded due to stock price evaluation, although it does not impact liquidity or cash flows.
• Sales Day Impact: Q4 growth was negatively affected by 4 fewer selling days, which contributed to a lower-than-expected performance.
• Market Dynamics: Concerns about potential headwinds from weather affecting elective procedures and competitive pressures in the orthopedic market.
• Execution Risks: Acknowledgment of missed execution opportunities in Q4, indicating a need for improved commercial discipline.

5. Notable Q&A Insights

• Free Cash Flow Improvement: Management highlighted ongoing productivity projects and reduced integration costs as key drivers for anticipated cash flow improvements.
• Arvis Rollout: The next-gen product is expected to launch in phases, with a flexible business model aimed at driving implant utilization.
• Market Growth Expectations: The company anticipates continued above-market growth in the Recon segment, particularly in extremities and hips.
• Portfolio Shaping: Management is focused on SKU rationalization and potential divestitures to enhance growth profiles and margins in the P&R segment.
• Strategic Focus: Emphasis on improving commercial execution and leveraging synergies between Recon and P&R segments to drive overall performance.

Overall, Enovis demonstrated resilience in a challenging operating environment, with a clear focus on growth and operational efficiency, while also acknowledging areas for improvement and potential market risks.